Researchers discovered that vitamin B12 can correct developmental problems in worms carrying a genetic mutation associated with Verheij syndrome, a rare human disorder characterized by developmental delays, impaired growth, and short stature.

The mutation disrupts RNA splicing, a cellular process that prepares genetic instructions for protein production. Scientists studied the mutation in C. elegans, a roundworm model organism. Worms with the mutation showed slowed growth and remained smaller than normal.

Genetic analysis revealed the mutation disrupted metabolic pathways dependent on vitamin B12. When researchers provided additional vitamin B12, the treatment restored these metabolic processes to normal and corrected the developmental abnormalities.

"We were surprised to find that a change in a fundamental process of RNA processing had such a targeted effect on vitamin B12-dependent metabolism," says Jonathan Kölschbach, first author of the study. "Even more exciting was that we were able to largely correct the consequences of this change in the worm model using vitamin B12."

The team examined publicly available datasets from human cells and collected blood samples from patients with Verheij syndrome in collaboration with Hormos Dafsari, a neuropediatrician at the University Hospital Cologne. The investigations found similar metabolic changes in humans, suggesting vitamin B12-related pathways may play a role in the human disorder.

However, researchers have not yet tested whether vitamin B12 supplementation improves symptoms in people with Verheij syndrome. Additional studies are necessary to determine whether the worm results translate to human treatment.

Adam Antebi, Director at the Max Planck Institute for Biology of Ageing and lead author of the study, noted the findings suggest metabolic disruptions may contribute more substantially to diseases caused by faulty RNA splicing than previously recognized.